Innoviva Inc (INVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Innoviva Inc (INVA) has a cash flow conversion efficiency ratio of 0.042x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($51.97 Million) by net assets ($1.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see INVA market cap for the company's overall valuation and market capitalisation.
Innoviva Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Innoviva Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Innoviva Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Innoviva Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Innoviva Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Vazyme Biotech Co Ltd
SHG:688105
|
0.021x |
|
IGNITIS GRUPE AB EO 2233
F:IGV0
|
0.048x |
|
OliX PharmaceuticalsInc
KQ:226950
|
-0.039x |
|
Latigo Biotherapeutics, Inc. Common Stock
NASDAQ:LTGO
|
0.077x |
|
Fujian Snowman Co Ltd
SHE:002639
|
-0.035x |
|
Companhia Siderúrgica Nacional
MX:SIDN
|
0.023x |
|
Perpetual Ltd
AU:PPT
|
0.035x |
|
Corporativo GBM S.A.B. de C.V
MX:GBMO
|
-0.026x |
Annual Cash Flow Conversion Efficiency for Innoviva Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Innoviva Inc from 2002 to 2025. View Innoviva Inc (INVA) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.17 Billion | $196.93 Million | 0.168x | -38.50% |
| 2024-12-31 | $691.16 Million | $188.69 Million | 0.273x | +30.63% |
| 2023-12-31 | $674.96 Million | $141.06 Million | 0.209x | -41.38% |
| 2022-12-31 | $565.79 Million | $201.73 Million | 0.357x | -48.46% |
| 2021-12-31 | $525.93 Million | $363.81 Million | 0.692x | +34.29% |
| 2020-12-31 | $607.84 Million | $313.11 Million | 0.515x | -31.55% |
| 2019-12-31 | $342.12 Million | $257.46 Million | 0.753x | -46.45% |
| 2018-12-31 | $159.05 Million | $223.53 Million | 1.405x | +340.64% |
| 2017-12-31 | $-242.71 Million | $141.75 Million | -0.584x | -238.05% |
| 2016-12-31 | $-352.99 Million | $60.98 Million | -0.173x | -458.49% |
| 2015-12-31 | $-327.50 Million | $10.13 Million | -0.031x | -105.29% |
| 2014-12-31 | $-223.35 Million | $-130.72 Million | 0.585x | +235.08% |
| 2013-12-31 | $299.12 Million | $-129.60 Million | -0.433x | +47.50% |
| 2012-12-31 | $155.03 Million | $-127.95 Million | -0.825x | -181.33% |
| 2011-12-31 | $-87.05 Million | $-88.34 Million | 1.015x | -69.72% |
| 2010-12-31 | $-22.42 Million | $-75.14 Million | 3.352x | +990.94% |
| 2009-12-31 | $-188.99 Million | $-58.06 Million | 0.307x | -58.50% |
| 2008-12-31 | $-134.95 Million | $-99.91 Million | 0.740x | -53.00% |
| 2007-12-31 | $-66.26 Million | $-104.37 Million | 1.575x | +195.16% |
| 2006-12-31 | $63.31 Million | $-104.79 Million | -1.655x | -68.17% |
| 2005-12-31 | $59.58 Million | $-58.65 Million | -0.984x | -291.79% |
| 2004-12-31 | $190.37 Million | $-47.82 Million | -0.251x | -337.58% |
| 2003-12-31 | $-299.57 Million | $-31.68 Million | 0.106x | -58.15% |
| 2002-12-31 | $-231.93 Million | $-58.60 Million | 0.253x | -- |
About Innoviva Inc
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The com… Read more